HOME >> BIOLOGY >> NEWS
It's not all genetic: Common epigenetic problem doubles cancer risk in mice

lem that improperly turns on the copy of the IGF2 gene that should remain off.

Unlike most genes, the copy of IGF2 that should be silent depends only on which parent it came from, a situation called genomic imprinting. For IGF2, the copy inherited from the mother is always supposed to be turned off.

In the mice and in some people, however, cells lack the epigenetic "marks" that sit on the DNA and keep the maternally inherited copy turned off. As a result, cells make a double dose of the IGF2 protein and are said to have "loss of imprinting" of IGF2.

Although Feinberg and others have already noted an association between loss of imprinting of IGF2 and colon cancer in people, the current experiments were designed to find out whether the loss of imprinting is involved in cancer's development or just in its progression.

"Most researchers, including me, expect epigenetic differences to influence progression -- whether a tumor would grow slowly or quickly, or whether it would spread," says Feinberg. "But, in this case, our results show that loss of imprinting of IGF2 contributes to colon cancer's development in the mice. It doesn't cause tumors directly, but it creates an environment which is ripe for cancer to start."

Because precursor cells in the colon's lining had been identified as a likely starting point for tumors, Feinberg and his team tossed a cancer-causing genetic mutation into the mix. The IGF2 mice were crossed with mice carrying a mutation in a gene called APC, which had been tied to colon cancer by researchers studying families with excessive growths, or polyps, in the colon.

Mice with extra IGF2 and the APC mutation developed twice the number of tumors as mice with the mutation but whose IGF2 levels were normal. The tumors grew at the same rate in both sets of mice, suggesting that more tumors get started in the mice with extra IGF2, notes Feinberg.

"In the mice, loss of imprinting of IGF2 roughly d
'"/>

Contact: Joanna Downer
jdowner1@jhmi.edu
410-614-5105
Johns Hopkins Medical Institutions
24-Feb-2005


Page: 1 2 3

Related biology news :

1. Common environmental chemicals in diet affect fetal ovarian development
2. Common cancer gene sends death order to tiny killer
3. Common treatment for methamphetamine overdose may damage brain cells
4. Common genetic variation is linked to substantial risk for heart attack
5. Common fungicide causes long-term changes in mating behavior
6. DNA ends: Common tool, different job
7. Common gene version optimizes thinking -- but with a possible downside
8. Common mechanisms for viral DNA replication
9. Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia
10. Common cause of heart disease, diabetes may be treatable with malaria drug
11. Commonplace sugar compound silences seizures

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/9/2017)... The biomass boiler market report by Transparency Market Research ... in terms of revenue (US$ Mn) based on the ... boilers has been segmented on the basis of feedstock ... based on feedstock type, has been segmented into woody ... urban residues, and others. On the basis of product ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
Breaking Biology Technology:
Cached News: